title: Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.
abstract: In 2000, a French consensus conference proposed guidelines for the treatment of Parkinson's disease (PD). Since then, new drugs have been concocted, new studies have been published and clinicians have become aware of some drug-induced adverse effects that were little known in the past. This has led us to reconsider the recommendations published 16 years ago. Thus, the aim of the present review is to present the recent data related to the different medications and non-pharmacological approaches available for PD, with a special focus on early-stage PD. Levodopa (LD), dopamine agonists (DAs), catechol-O-methyltransferase inhibitors (COMT-Is), anticholinergics, monoamine oxidase inhibitors (MAOB-Is) and amantadine have been considered, and their efficacy and safety for both motor as well as non-motor aspects are reported here. This has led to our proposal for a revised therapeutic strategy for the initiation of treatment in newly diagnosed PD patients, based on the available literature and the relative benefits/side effects balance.
authors.affiliation: Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université de Lyon, université Claude-Bernard Lyon I, Lyon, France. Electronic address: chloe.laurencin@chu-lyon.fr.
authors.forename: C
authors.initials: C
authors.lastname: Laurencin
authors.affiliation: Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France.
authors.forename: T
authors.initials: T
authors.lastname: Danaila
authors.affiliation: Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France; CNRS, UMR 5229, institut des sciences cognitives Marc-Jeannerod, 69500 Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université de Lyon, université Claude-Bernard Lyon I, Lyon, France.
authors.forename: E
authors.initials: E
authors.lastname: Broussolle
authors.affiliation: Service de neurologie C, hôpital neurologique Pierre-Wertheimer, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon/Bron, France; CNRS, UMR 5229, institut des sciences cognitives Marc-Jeannerod, 69500 Bron, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université de Lyon, université Claude-Bernard Lyon I, Lyon, France.
authors.forename: S
authors.initials: S
authors.lastname: Thobois
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use*; D065098:Catechol O-Methyltransferase Inhibitors / Q000627:therapeutic use; D032921:Consensus; D003245:Consensus Statements as Topic; D018491:Dopamine Agonists / Q000627:therapeutic use; D005602:France; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors
keywords: Amantadine; Anticholinergics; Cathecol-O-methyltransferase inhibitors; Dopamine agonist; Levodopa; Monoamine oxidase B inhibitors; Parkinson's disease